Avelar Rui 4
4 · Evolus, Inc. · Filed Feb 19, 2026
Research Summary
AI-generated summary of this filing
Evolus CMO Rui Avelar Receives Award of 328,475 Units
What Happened Rui Avelar, Chief Medical Officer and Head of R&D at Evolus (EOLS), received three equity awards on February 17, 2026 totaling 328,475 units: 94,913 restricted stock units (RSUs), 94,913 performance-based restricted stock units (PSUs), and 138,649 option-based awards. All grants are reported at $0.00 (no cash was paid at grant). These awards are compensation grants, not open-market purchases or sales.
Key Details
- Transaction date: February 17, 2026; Form 4 filed February 19, 2026 (timely).
- Grants: 94,913 RSUs (F1); 94,913 PSUs (F2/F3); 138,649 option-based awards (F4).
- Price shown: $0.00 for all items — reflects a grant/award, not a paid purchase.
- Vesting/performance notes:
- RSUs vest in four equal annual installments on each anniversary of Feb 17, 2026, subject to service and possible acceleration (F1).
- PSUs pay 0–200% of target based on pre-established financial metrics and relative TSR over a three‑year performance period ending Dec 31, 2028; any earned PSUs vest after certification of results (F2, F3).
- Option-based awards vest in four equal annual installments on each anniversary of Feb 17, 2026, subject to service and possible acceleration (F4).
- Shares owned after the transaction: not reported in the filing.
Context These entries are awards/compensation (transaction code A) rather than open-market trades. PSUs are performance-contingent — the actual number of shares delivered could be up to 200% of target depending on performance and certification. The filing does not indicate any immediate sale or cashless exercise; this is a forward-looking compensation grant that vests over time or upon achievement of performance goals.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-17+94,913→ 451,734 total - Award
Performance Restricted Stock Units
[F2][F3]2026-02-17+94,913→ 94,913 total→ Common Stock (94,913 underlying) - Award
Stock Option (Right to Buy)
[F4]2026-02-17+138,649→ 138,649 totalExercise: $4.39Exp: 2036-02-17→ Common Stock (138,649 underlying)
Footnotes (4)
- [F1]Represents shares issuable upon settlement of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each anniversary of February 17, 2026, subject to continued service, and may accelerate in certain circumstances (including specified terminations or a change in control).
- [F2]Each performance-based restricted stock unit (PSU) represents the right to receive, following vesting, a number of shares of common stock of the issuer up to 200% of the number of PSUs.
- [F3]The number of shares issuable upon vesting is based on performance against pre-established financial metrics and relative total shareholder return (TSR) over a three-year performance period ending December 31, 2028. Subject to certification of performance results, any earned PSUs vest following the performance period.
- [F4]The shares subject to the option vest in four equal annual installments on each anniversary of February 17, 2026, subject to continued service, and may accelerate in certain circumstances (including specified terminations or a change in control).